Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 1

Status

Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, B-Cell 3Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Burkitt Lymphoma 2Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 146Rituximab 138fludarabine phosphate 111Mycophenolic Acid 69Peripheral Blood Stem Cell Transplantation 63fludarabine 59Tacrolimus 58Whole-Body Irradiation 51venetoclax 46Busulfan 46ibrutinib 45Cyclosporine 42Lenalidomide 41Filgrastim 41Alemtuzumab 41Melphalan 40Radiotherapy 39obinutuzumab 37Antilymphocyte Serum 35Etoposide 33Methotrexate 32ofatumumab 29acalabrutinib 26Bendamustine Hydrochloride 24sargramostim 22Methylprednisolone 18Cytarabine 18zanubrutinib 17Pentostatin 17Granulocyte Colony-Stimulating Factor 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphocytic, Chronic, B-Cell × tafasitamab × Clear all
NCT07582159 2026-05-12

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05718869 2026-05-08

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

City of Hope Medical Center

Phase 2 Active not recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
41 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02639910 2021-12-20

COSMOS

MorphoSys AG

Phase 2 Completed
24 enrolled 13 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡